US 8962643
Compositions and methods for inhibition of the JAK pathway
granted A61KA61K31/505A61K31/506
Quick answer
US patent 8962643 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K31/505, A61K31/506, A61K45/06, A61P